|Articles|June 8, 2022
Tissue IHC: Translating Technology into Patient Testing After Biomarker Target is ID
Author(s)Frontage Laboratories, Inc.
In the discovery and investigation of novel biomarkers, tissue immunohistochemistry (IHC) studies are critical, but how do you translate the technology into the clinical laboratory for patient testing once a biomarker target has been identified?
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Content
Trending on Applied Clinical Trials Online
1
Partners for Success: Governance Best Practices to Streamline eCOA Trial Launch
2
Drug Repurposing Through AI-Driven In-Silico Clinical Trials
3
Former FDA Commissioners Warn New Vaccine Policies Could Undermine Longstanding Regulatory Framework
4
Balancing Innovation and Compliance under New GCP Guidelines
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
